子宫内膜异位症组织中hMLH1、hMSH2蛋白的表达及意义  

Expression of h MLH1,h MSH2 protein and their significance in endometriosis

作　　者：薛思玲 曹保利[2] 

机构地区：[1]天津医科大学,天津300070 [2]天津市南开医院

出　　处：《山东医药》2014年第42期11-13,共3页Shandong Medical Journal

基　　金：天津市中医;中西医结合科研专项基金资助项目(11014)

摘　　要：目的观察人类错配修复基因h MLH1、h MSH2蛋白在子宫内膜异位症(EMS)病灶组织中的表达变化并探讨其意义。方法选择28例EMS患者的子宫内膜异位病灶组织作为病例组,其中Ⅲ期14例、Ⅳ期14例。选择因子宫肌瘤行子宫全切术的26例患者的正常子宫内膜组织作为对照组。采用免疫组化SP法检测两组h MLH1、h MSH2蛋白的表达。比较两组h MLH1、h MSH2蛋白的阳性率,比较病例组Ⅲ、Ⅳ期患者h MLH1、h MSH2蛋白的阳性率。结果病例组、对照组h MLH1蛋白阳性率分别为71.4%(20/28)、30.8%(8/26),病例组h MLH1蛋白阳性率高于对照组(P<0.01)。病例组、对照组h MSH2蛋白的阳性率分别为53.6%(15/28)、57.7%(15/26),两组h MSH2蛋白表达差异无统计学意义。病例组Ⅲ、Ⅳ期患者h MLH1、h MSH2蛋白的阳性率差异无统计学意义(P均>0.05)。结论 EMS组织h MLH1蛋白表达增高,h MLH1蛋白表达增高可能与EMS的发病有关。Objective To study the relationship between the human mismatch repair gene（ h MLH1,h MSH2） protein expression and endometriosis（ EMS）. Methods A total of 28 EMS tissues were involved as case group,including 14 cases of Ⅲ stage and 14 cases of Ⅳ stage. The control group tissues were cut from normal uterus tissues of 26 laparoscopic patients after myomectomy. The expression of h MLH1 and h MSH2 protein in the two groups were measured by immunohistochemical SP technique. The positive rate of h MLH1 and h MSH2 protein in two groups was compared. The positive rate of h MLH1 and h MSH2 protein in Ⅲ,Ⅳ phase of endometriosis in case group was compared. Results The positive rate of h MLH1 protein in case group and control group was 71. 4%（ 20 /28）,30. 8%（ 8 /26）,respectively. The expression of h MLH1 protein in case group was higher than that in control group（ P〈0. 01）. The positive rate of h MLH2 protein in control group and control group was 53. 6%（ 15 /28）,57. 7%（ 15 /26）,respectively. The expression of h MLH2 protein in two groups was no significant difference. The expression of h MLH1 and h MLH2 in Ⅲ,Ⅳ phase patients was no significant difference. Conclusions The expression of h MLH1 protein increased in EMS tissues,which indicates that h MLH1 protein may be related with the development of EMS.

关 键 词：子宫内膜异位症 人类错配修复基因 DNA错配修复 

分 类 号：R711.71[医药卫生—妇产科学]